Navigation Links
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Date:11/18/2011

ts in EYLEA.

The recommended dose for EYLEA is 2 mg administered by intravitreal injection every four weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every eight weeks (2 months).  Although EYLEA may be dosed as frequently as 2 mg every four weeks (monthly), additional efficacy was not demonstrated when EYLEA was dosed every four weeks compared to every eight weeks.

There is a potential risk of arterial thromboembolic events (ATEs) following use of intravitreal VEGF inhibitors, including EYLEA, defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).  The incidence of ATEs with EYLEA in clinical trials was low (1.8%).

Serious adverse reactions related to the injection procedure have occurred in less than 0.1% of intravitreal injections with EYLEA and include endophthalmitis, traumatic cataract, and increased intraocular pressure.

About the VIEW 1 and VIEW 2 Clinical StudiesThe safety and efficacy of EYLEA were assessed in two randomized, multi-center, double-masked, active-controlled studies in patients with wet AMD.  A total of 2412 patients were treated and evaluable for efficacy (1817 with EYLEA) in the two studies (VIEW 1 and VIEW 2). In each study, patients were randomly assigned in a 1:1:1:1 ratio to one of four dosing regimens: 1) EYLEA administered 2 mg every eight weeks following three initial monthly doses (EYLEA 2Q8); 2) EYLEA administered 2 mg every four weeks (EYLEA 2Q4); 3) EYLEA 0.5 mg administered every four weeks (EYLEA 0.5Q4); and 4) ranibizumab administered 0.5 mg every four weeks (ranibizumab 0.5Q4).  Patient ages ranged from 49 to 99 years with a mean of 76 years.

In both studies, the primary efficacy endpoint was the proportion of patients who maintained vision, defined as losing fewer than 15 letters of visual acuity at week 52 compared to baseline.  Data are available through week 52.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
2. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
3. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
4. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
5. Regeneron Reports Second Quarter 2011 Financial and Operating Results
6. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
7. Trading in Regeneron Common Stock Halted
8. Regeneron Reports First Quarter 2011 Financial and Operating Results
9. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
11. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets has ... Medical X-ray Film Industry Report 2014" report to ... Global And Chinese Medical X-Ray Film Industry ... the current state of the Global medical X-ray film ... The report provides a basic overview of the industry ...
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... financial results for the fourth quarter and fiscal year ... Completed construction of new global headquarters ... relocated entire staff (December 2010) Appointed Dr. Ramin ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... and Chief Executive Officer, will provide an overview and update ... Healthcare Conference on Tuesday, September 13, 2011 at 1:35 pm ... York City. The presentation will be webcast live and can ...
Cached Medicine Technology:Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 2Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 3Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 4Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 5Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 6Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 7Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 8Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 9Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011 10
(Date:7/13/2014)... MillionaireCasket.com is a professional supplier of funeral ... caskets are selling well in the global market. Recently, the ... and launched a special offer for all the newly ... the company’s cherry caskets are made with superb materials. As ... people to show respect to the departed saint. MillionaireCasket.com is ...
(Date:7/13/2014)... get the best treatment and variations in the quality ... for blood cancer patients still varies widely between regions ... survival in European adults to date, published in ... that 5-year survival for most cancers of the blood ... reflecting the approval of new targeted drugs in the ...
(Date:7/13/2014)... Carolinas Healthcare System celebrated today the ... HealthCare System - Anson located in Anson County. The ... Hospital in Wadesboro. , Located on U.S. Highway 74, ... previous facility. Situated on a 10-acre site, the new ... room drop-off, helipad, healing garden, and 15 beds. With ...
(Date:7/13/2014)... research in Nature Genetics identifies a ... that causes eosinophillic esophagitis (EoE), opening up potential ... food allergy. , EoE is a chronic ... triggered by allergic hypersensitivity to certain foods and ... cells called eosinophils (part of the body,s immune ...
(Date:7/13/2014)... July 13, 2014 Chromatography system ... components from various types of biological samples such ... the sample mixture into two phase, namely mobile ... mobile phase run over the stationary phase, followed ... components that provide the separation of mixture. Chromatography ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3
... direct marketing promotional products company, offers a specialty store filled ... ... Lewiston, ME (PRWEB) February 19, 2009 -- Crestline ... that trades on its easy, customer-friendly ordering process, offers ...
... Natrecor for a Use Not Approved By the Food ... has intervened in two whistleblower suits filed in the ... Inc. and its parent company, Johnson & Johnson Inc., ... for a use not approved by the Food and ...
... Indicates a 40% Reduction of Intraocular Pressure at Two ... today that it has surpassed 1000 implantation procedures with ... reduces intraocular pressure (IOP) for the treatment of glaucoma. ... President and Founder of SOLX, "as it validates the ...
... to Consumer-Directed Health Plans Continues, Watson Wyatt/National Business Group ... expect health care cost increases to hold steady at ... plans (CDHPs) in 2010 in an effort to control ... Wyatt, a leading global consulting firm, and the National ...
... to risk-taking, too, study finds, , , THURSDAY, Feb. ... makes people love skydiving, mountain-climbing or other intense ... the brain that has been linked to addictive ... researchers studied volunteers who were grouped as either ...
... percent less likely than men to receive a critical ... stroke, according to a Michigan State University study. , ... Diego at the International Stroke Conference, organized by the ... plasminogen activator, or tPA, first approved as a treatment ...
Cached Medicine News:Health News:Crestline is the Source for Great Green Giveaways 2Health News:Crestline is the Source for Great Green Giveaways 3Health News:United States Joins Suits Against Scios and Johnson & Johnson 2Health News:United States Joins Suits Against Scios and Johnson & Johnson 3Health News:SOLX Announces 1000th Gold Shunt Implantation Milestone for Glaucoma Treatment 2Health News:Health Care Benefit Cost Increases to Remain at 6 Percent in 2009 2Health News:Health Care Benefit Cost Increases to Remain at 6 Percent in 2009 3Health News:Thrill-Seekers' Brains May Be Wired Differently 2Health News:Women less likely to receive critical care after a stroke, MSU researchers find 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: